A novel tumor-associated antigen expressed in human uterine and ovarian carcinomas

Sonoda, Kenzo; Nakashima, Mitsuyoshi; Kaku, Tsunehisa; Kamura, Toshiharu; Nakano, Hitoo; Watanabe, Takeshi

doi:10.1002/(sici)1097-0142(19960415)77:8<1501::aid-cncr12>3.0.co;2-3

Cited by 116 publications

(128 citation statements)

References 38 publications

Supporting

Mentioning

124

Contrasting

Order By: Relevance

“…In gynaecological malignancies, Kaku et al (1999) reported that patients with high RCAS1 expression showed significantly worse overall survival than those with low expression in adenocarcinoma of uterine cervix. In addition, Sonoda et al (1998) reported that RCAS1 was not detected in the normal uterine cervix or ovarian tissue, but strongly expressed in uterine endometrial adenocarcinomas, ovarian adenocarcinomas (Sonoda et al, 1996;Sonoda et al, 2000) and cervical squamous cell carcinomas. Recently, Suzuki et al (2001) reported that EBAG9 immunoreactivity was detected in 82 of 91 in breast carcinoma (90.1%), although it was not associated with clinicopathological parameters.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Expression of EBAG9/RCAS1 is associated with advanced disease in human epithelial ovarian cancer

Aoki

Suzuki

et al. 2004

Br J Cancer

View full text Add to dashboard Cite

Oestrogen receptor-binding fragment associated gene 9, EBAG9, is an oestrogen-responsive gene that was identified in MCF-7 human breast carcinoma cell line. It is identical to RCAS 1, a cancer cell surface antigen possibly involved in immune escape. In the present study, we examined the expression of EBAG9/RCAS1 in human epithelial ovarian cancer using immunohistochemistry, immunoblotting and reverse transcription -polymerase chain reaction (RT -PCR). A total of 90 epithelial ovarian cancer cases were examined immunohistochemically by means of the antibodies for EBAG9 and ERa. The correlation between EBAG9 immunoreactivity and clinicopathological parameters was examined. mRNA expression of EBAG9 and ERa were evaluated by RT -PCR in 22 cases. The expression for EBAG9 and ERa was examined by immunoblotting in 12 ovarian cancer cell lines. EBAG9 immunoreactivity was detected in the surface and cytoplasm of carcinoma cells in 46 out of 90 cases (51.1%). EBAG9 expression was significantly higher in serous histology (P ¼ 0.0402) and advanced disease (P ¼ 0.0206). No significant relationship was detected between EBAG9 immunoreactivity and overall survival (P ¼ 0.689). There was a highly significant correlation between EBAG9 and ER immunoreactivity (Po0.0001). The EBAG9 mRNA was detected in 20 out of 22 cases. In all of the cases that were positive for ERa mRNA, they were also positive for EBAG9 mRNA. Immunoreactive band corresponding to EBAG9 was detected in 11 out of 12 of ovarian cancer cell lines, and was consistent with ERa expression. In conclusion, the wide distribution of EBAG9 and its relation to advanced disease suggest that this protein may play important roles in epithelial ovarian cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Others reported that RCAS1 is associated with poor prognosis and/or advanced stage in various human cancers (Sonoda et al, 1996;Kaku et al, 1999;Izumi et al (2001); Nakakubo et al, 2002). However, the expression of EBAG9 and its clinical significance have not been examined in epithelial ovarian cancer.…”

mentioning

confidence: 99%

Expression of EBAG9/RCAS1 is associated with advanced disease in human epithelial ovarian cancer

Aoki

Suzuki

et al. 2004

Br J Cancer

View full text Add to dashboard Cite

show abstract

“…Immunohistochemically, expression of RCAS1 has been detected in uterine and ovarian carcinomas, especially in invasive tumors (10,11). However, RCAS1 has not been detected in normal uterine and ovarian tissues (10).…”

Section: Discussionmentioning

confidence: 99%

“…However, RCAS1 has not been detected in normal uterine and ovarian tissues (10). In addition, RCAS1 is highly expressed on invasive carcinomas (11), and expression of RCAS1 is correlated with poor prognosis in uterine cancers (17).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Immunohistochemical Analysis of RCAS1 in Human Pituitary Adenomas

et al. 2001

Self Cite

View full text Add to dashboard Cite

Expression of tumor-associated antigen RCAS1 correlates significantly with poor prognosis in nonsmall cell lung carcinoma

Izumi

Nakanishi

Yoshino

et al. 2001

Cancer

Self Cite

View full text Add to dashboard Cite

BACKGROUND RCAS1 is a recently discovered antigen molecule expressed on the membrane of cancer cells, and it acts as a ligand for a putative receptor present on immune cells such as T, B and NK cells. It has been suggested that RCAS1 expression is related to the escape of tumors from immune surveillance. In this study, the relation between RCAS1 expression and various clinicopathologic variables, including patient prognosis, was investigated in lung carcinoma through immunohistochemical analysis. METHODS One hundred two surgically resected nonsmall cell lung carcinoma cases were examined histopathologically by means of the monoclonal antibody 22‐1‐1, which is specific for RCAS1. The correlation between RCAS1 expression and the clinicopathologic features of patients was evaluated. Moreover, the correlation between RCAS1 expression and the survival of patients was analyzed by the Kaplan–Meier method log‐rank test, and multivariate analysis was performed by using the Cox proportional hazard model. RESULTS The samples of 48 of the 102 lung carcinoma patients (47.1%) were positive for RCAS1. There were significant correlations between RCAS1 expression and either pathologic staging (P = 0.0003) or tumor differentiation (P = 0.0308). The survival time for the RCAS1‐positive group was significantly shorter than that for RCAS1‐negative group (P < 0.0001). Moreover, multivariate analysis for overall survival revealed that RCAS1 expression was a significantly independent prognostic factor in nonsmall cell lung carcinoma patients. CONCLUSION These results suggested that RCAS1 expression may play an important role in the immune escape mechanism and that RCAS1 expression may be a good indicator of poor prognosis in patients with nonsmall cell lung carcinoma. Cancer 2001;92:446–51. © 2001 American Cancer Society.

show abstract

A novel tumor-associated antigen expressed in human uterine and ovarian carcinomas

Abstract: BACKGROUND.A large number of monoclonal antibodies (MoAhs) against human

Cited by 116 publications

References 38 publications

Expression of EBAG9/RCAS1 is associated with advanced disease in human epithelial ovarian cancer

Expression of EBAG9/RCAS1 is associated with advanced disease in human epithelial ovarian cancer

Immunohistochemical Analysis of RCAS1 in Human Pituitary Adenomas

Expression of tumor-associated antigen RCAS1 correlates significantly with poor prognosis in nonsmall cell lung carcinoma

Contact Info

Product

Resources

About